Attention deficit hyperactivity disorder management

Attention deficit hyperactivity disorder management is the treatment options available to people with attention-deficit/hyperactivity disorder (ADHD).

There are several effective and clinically proven options to treat people with ADHD. Combined medical management and behavioral treatment is the most effective ADHD management strategy, followed by medication alone, and then behavioral treatment.[1] However, these results have been questioned because the study from the multimodal treatment group faded the behavioral procedure 3 months prior to the last evaluation point but continued the medication group.[2] Indeed, after 14 months the medication group lost its advantage to the long discontinued behavior modification group.[3] By year eight socioeconomic status and family structure were the only predictive variable for ADHD treatment[4] A separate study highlighted the influence that nonclinical factors such as family size may have in mediating the use of pharmacologic therapies for children with ADHD.[5]

The most common stimulant medications are methylphenidate (Ritalin), dextroamphetamine (Dexedrine), and mixed amphetamine salts (Adderall).[6] Atomoxetine (Strattera) and Guanfacine (Intuniv) are non-stimulant drugs approved for the treatment of ADHD.[7] Other medications which may be prescribed off-label include certain antidepressants such as tricyclic antidepressants, SNRIs or MAOIs.[8][9][10] The presence of comorbid (relating to two diseases that occur together, e.g. depression and ADHD) disorders make finding the right treatment and diagnosis much more costly and time consuming.

A variety of psychotherapeutic and behavior modification approaches to managing ADHD including psychotherapy and working memory therapy may be used. Improving the surrounding home and school environment with parent management training and classroom management can improve the behavior of children with ADHD.[11] Specialized ADHD coaches provide services and strategies to improve functioning, like time management or organizational suggestions. Self control training programs have shown to have limited effectiveness.[12] Behaviorally based self control does better than cognitive self control training[13] A meta-analysis found that the use of behavior modification for ADHD are effective.[14]

As of 2006 there was a shortage of data regarding ADHD drugs' potential adverse effects,[15] with very few studies assessing the safety or efficacy of treatments beyond four months,[16] and no randomized controlled trials assessing for periods of usage longer than two years.[17][18] Treatment of preschool children is not recommended.[19] The U.S. Food and Drug Administration (FDA) found that a large number of the controlled trials required subjects who were known to respond to stimulants or who had no history of intolerance to stimulants, and this limits assumed generalizability of the trials' results.[20]

Contents

Psychosocial

There are a variety of psychotherapeutic approaches employed by psychologists and psychiatrists; the one used depends on the patient and the patient's symptoms. The approaches include psychotherapy, cognitive-behavior therapy, support groups, parent training, meditation, and social skills training. If psychotherapy fails to bring improvement, medications can be considered as an add-on or alternative.[21][22][23]

Psychotherapy

Psychotherapy is another option, with or without medication, that has been shown to be effective.[24]

Parent education and classroom management

Improving the surrounding home and school environment can improve the behavior of children with ADHD.[11] Parents of children with ADHD often show similar deficits themselves, and thus may not be able to sufficiently help the child with his or her difficulties.[25] Improving the parents' understanding of the child's behavior and teaching them strategies to improve functioning and communication and discourage unwanted behavior has measurable affect on the children with ADHD.[11] The different educational interventions for the parents are jointly called Parent Management Training. Techniques include operant conditioning: a consistent application of rewards for meeting goals and good behavior (positive reinforcement) and punishments such as time-outs or revocation or privileges for failing to meet goals or poor behavior.[11] Classroom management is similar to parent management training; educators learn about ADHD and techniques to improve behavior applied to a classroom setting. Strategies utilized include increased structuring of classroom activities, daily feedback, and token economy.[11]

Working memory training

Main article: Working memory training
Main article: Treatment of ADHD through working memory training

Many of the problems shown by children with ADHD can be traced back to deficits in working memory (or short-term memory). By training and improving this memory some of the other symptoms may diminish as well. In a study by Klingberg et al., a computerized training program has shown good results in working memory, even if the generalized effect to behavioural symptoms was not as clear.[26]

Coaching

ADHD Coaching is a specialized type of life coaching that uses specific techniques geared toward working with the unique brain wiring of individuals with attention-deficit/hyperactivity disorder. Professional coaching is not considered a substitute for traditional treatment such as medication and therapy.

Medications

Stimulants

Stimulants are the most commonly prescribed medications for ADHD. The most common stimulant medications are the chain subsitituted amphetamine methylphenidate (Ritalin, Metadate, Concerta), dexmethylphenidate (Focalin), dextroamphetamine (Dexedrine), mixed amphetamine salts(Adderall),[27][28] dextromethamphetamine(Desoxyn)[29] and lisdexamfetamine (Vyvanse).[30] However, caution needs to be used when prescribing medications that increase levels of "feel-good" neurotransmitters like dopamine, because they can be addictive (see article: amphetamine dependence).[31][32] According to several studies, use of stimulants (e.g. methylphenidate) can lead to development of drug tolerance to therapeutic doses; tolerance also occurs among high dose abusers of methylphenidate.[33][34][35]

Stimulants used to treat ADHD raise the extracellular concentrations of the neurotransmitters dopamine and norepinephrine which causes an increase in neurotransmission. The therapeutic benefits are due to noradrenergic effects at the locus coeruleus and the prefrontal cortex and dopaminergic effects at the nucleus accumbens.[36]

A meta analysis of clinical trials found that about 70 percent of children improve after being treated with stimulants in the short term but found that this conclusion may be biased due to the high number of low quality clinical trials in the literature. There have been no randomized placebo controlled clinical trials investigating the long term effectiveness of methylphenidate(Ritalin) beyond 4 weeks. Thus the long term effectiveness of methylphenidate has not been scientifically demonstrated. Serious concerns of publication bias regarding the use of methylphenidate for ADHD has also been noted.[37]

Higher rates of schizophrenia and bipolar disorder as well as increased severity of these disorders occur in individuals with a past history of stimulant use for ADHD in childhood.[38] Emergency room visits by children ages 10–14 involving Ritalin intoxication have now reached the same level as those for cocaine which indicates escalating abuse of this highly addictive drug.[39] US and Canada account for a startling 95 percent of worldwide Ritalin consumption.[39][40]

Both children with and without ADHD abuse stimulants, with ADHD individuals being at the highest risk of abusing or diverting their stimulant prescriptions. Between 16 and 29 percent of students who are prescribed stimulants report diverting their prescriptions. Between 5 and 9 percent of grade/primary and high school children and between 5 and 35 percent of college students have used nonprescribed stimulants. Most often their motivation is to concentrate, improve alertness, "get high," or to experiment.[41]

One review indicates that long-term use of methylphenidate has potential for abuse and addiction due to its similarity pharmacologically to cocaine and amphetamines.[42][43] However, other doctors argue that use of stimulant therapy for ADHD does not increase the risk of subsequent substance abuse and may be protective against it when treatment is started in childhood. However, when stimulant therapy is started during adolescence or adulthood, there is an increased risk of subsequent substance abuse.[44][45]

One study found that children with ADHD actually need to move more to maintain the required level of alertness while performing tasks that challenge their working memory. Performing math problems mentally and remembering multi-step directions are examples of tasks that require working memory, which involves remembering and manipulating information for a short time. These findings may also explain why stimulant medications improve the behavior of most children with ADHD. Those medications improve the physiological arousal of children with ADHD, increasing their alertness.[46] Previous studies have shown that stimulant medications temporarily improve working memory abilities.

Although "under medical supervision, stimulant medications are considered safe",[11][47] the use of stimulant medications for the treatment of ADHD has generated controversy because of undesirable side effects, uncertain long term effects[18][48][49][50][51] and social and ethical issues regarding their use and dispensation. The U.S. FDA has added black-box warnings to some ADHD medications,[52][53] while the American Heart Association and the American Academy of Pediatrics feel that it is prudent to carefully assess children for heart conditions before treating them with stimulant medications.[54]

A novel stimulant drug that has been used to treat ADHD is modafinil. There have been double-blind randomized controlled trials that have demonstrated the efficacy and tolerability of modafinil,[55][56] however there are risks of serious side effects such as skin reactions and modafinil is not recommended for use in children.[57]

Stimulants are the most effective medications available for the treatment of ADHD.[1] Five different formulations of stimulants have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD: three derived from amphetamine and two derived from methylphenidate. Atomoxetine is the only non-controlled, non-stimulant FDA-approved drug for the treatment of ADHD. There are no differences in effectiveness between medications used for ADHD.[58]

Short term clinical trials have shown medications to be effective for treating ADHD, but the trials usually use exclusion criteria, meaning knowledge on medications for ADHD is based on a small subset of the typical patients seen in clinical practice.[59] They have not been found to improve school performance and data is lacking on long term effectiveness and the severity of side effects.[60] This class of medicines is generally regarded as one unit;[61] however, they affect the brain differently.[62] Some investigations are dedicated to finding the similarities of children who respond to a specific medicine.[62] The behavioural response to stimulants in children is similar regardless of whether they have ADHD or not.[63]

Stimulant medication is an effective treatment[64] for Adult Attention-deficit hyperactivity disorder[65][66] although the response rate may be lower for adults than children.[67] Some physicians may recommend antidepressant drugs as the first line treatment instead of stimulants[68] although antidepressants have lower treatment effect sizes than stimulant medication.[69]

A study shown that children taking stimulant medications tend to be lighter in weight and shorter than their peers.[70]

Amphetamines

Three different medicines derived from amphetamine are used in ADHD treatment. Their trade names are Adderall (a mixture of 72% dextroamphetamine and 28% levoamphetamine), Dexedrine (pure dextroamphetamine), and Desoxyn (pure dextromethamphetamine).[71] The differences in these three Amphetamine based medications' active compounds and mixture ratios results in each medications' slightly different activities.

Levoamphetamine and dextroamphetamine

Levoamphetamine and dextroamphetamine have the same chemical formula but are mirror images of each other, the same way that a person's hands are the same but are mirror images of each other. This mirror difference is enough to cause the two compounds to be metabolized differently. Adderall begins to work before dextroamphetamine because of levoamphetamine.[72] Levoamphetamine also provides Adderall with a longer clinical effect than dextroamphetamine. However, the brain’s preference for dextroamphetamine over levoamphetamine shows that the clinical value of Adderall is, for the most part, due to dextroamphetamine.[72] A few children with ADHD and comorbid disorders have helpful responses to levoamphetamine.[62]

Dextromethamphetamine

The body metabolizes dextromethamphetamine into dextroamphetamine (in addition to less important chemicals). A quarter of dextromethamphetamine will ultimately become dextroamphetamine.[73] After comparing only the common ground between dextroamphetamine and dextromethamphetamine, the latter is said to be the stronger stimulant.[74] In theory—and in practice—a larger dose of dextroamphetamine is needed to achieve dextromethamphetamine’s clinical potency. In fact, when dextroamphetamine and methylphenidate are unhelpful, some doctors may prescribe dextromethamphetamine. Although more rarely prescribed, anecdotal reports suggest dextromethamphetamine is very helpful in cases where the other two are ineffective, or cause limiting side effects.[75]

Methylphenidate based medications

There are two different medicines derived from methylphenidate: Ritalin, which is half dextrothreomethylphenidate and half levothreomethylphenidate, and Focalin, which is pure dextrothreomethylphenidate. Dextrothreomethylphenidate has a higher pharmacological activity than its mirror levo-form or enantiomer. Levothreomethylphenidate has much weaker activity than the dextro isomer, and so for instance if Daytrana (Ritalin in transdermal patch form) is used, then the levothreomethylphenidate comprising half of the administered dose, accounts for only around one thirteenth of the total clinical effect.[76] Methylphenidate has high potential for abuse and addiction due to its pharmacological similarity to cocaine and amphetamines.[77][78]

Formulations

Controlled release pharmaceutical may allow once daily administration of medication in the morning. This is especially helpful for children who do not like taking their medication in the middle of the school day. Several controlled release methods are used.

Non stimulants

Atomoxetine (Strattera) and guanfacine (Intuniv) are the only non-stimulant drugs approved for the treatment of ADHD. Other medications which may be prescribed off-label include α2A adrenergic receptor agonists such as clonidine, certain antidepressants such as tricyclic antidepressants, SNRIs, SSRIs or MAOIs.[79][80][81][82]

Atomoxetine (Strattera) is less effective than stimulants for ADHD, is associated with individual cases of liver damage, carries a U.S. FDA black box warning regarding suicidal idealization, and controlled studies show increases in heart rate, decreases of body weight, decreased appetite and treatment-emergent nausea.[83]

Intuniv is an extended release form of guanfacine. Intuniv has been approved by the FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in children as an alternative to stimulant medications. Its beneficial actions are likely due to its ability to strengthen prefrontal cortical regulation of attention and behavior.[84]

Certain antidepressants such as tricyclic antidepressants, SNRIs or MAOIs are sometimes prescribed and are also effective in the treatment of ADHD.[8][9][10][85]

Other

Some medications used to treat ADHD are prescribed off-label,[86] outside the scope of their FDA-approved indications for various reasons. The U.S. FDA requires two clinical trials to prove a potential drug's safety and efficacy in treating ADHD. The drugs below have not been through these tests, so the efficacy is unproven (however these drugs have been licensed for other indications, so have been proven to be safe in those populations), however proper dosage and usage instructions are not as well characterized.

Antipsychotic medication

The use of atypical antipsychotic medication as an off-label treatment has been rising.[94] Antipsychotics work by blocking dopamine, whereas stimulants trigger its release. Atypical antipsychotics have been approved for use in children and teenagers with schizophrenia spectrum disorders and autistic spectrum disorders by the U.S. FDA.[95]

Non-ADHD children do not respond differently than ADHD children when prescribed antipsychotic drugs, which are also increasingly prescribed off-label for children with aggression or defiant behavior.[96] Social pressure to control a child's difficult and disruptive behavior, both at home and at school, may inadvertently change focus from what is in the best interest of the child's wellbeing; to how to render the child more compliant and easier to manage.

Careful approach needs to be taken when blocking dopamine function, which is responsible for the psychological reward system. Excessive blocking of this neurotransmitter can causedysphoria. This may in turn cause suicidal ideation, or lead some teenagers to compensate for their dopamine deficiency with illicit drugs or alcohol. Atypical antipsychotics are preferred for this reason, because they are less likely to cause movement disorders, dysphoria, and increased drug cravings that have been associated with older typical antipsychotics.[97]Weight gain, diabetes, lactation, gynecomastia, drooling, dysphoria, anhedonia (inability to experience pleasure), fatigue, sexual dysfunction, heart rhythm problems and the possibility of tardive dyskinesia, an irreversible movement disorder, are among the adverse events associated with antipsychotic drugs.

Concerns regarding stimulants

See also: Attention-deficit hyperactivity disorder controversies

The National Institute of Mental Health states that, "stimulant drugs, when used with medical supervision, are usually considered quite safe."[98] Still, some parents and professionals have raised questions about the side effects of drugs and their long term use.[99] A recent review states that ADHD studies "have major methodological deficiencies which are compounded by their restriction to school-age children, relatively short follow-up, and few data on adverse effects."[17]

The American Heart Association feel that it is prudent to carefully assess children for heart conditions before treating them with stimulant medications.[100] Several studies have found growth and weight suppression for stimulants.[101] Compared to the behavior modification group at 8 years of the government-funded MTA study, the stimulant group had higher level of reported substance abuse.[102]

Increase in use

Outpatient treatment rates have held steady in the US recently.[103] Prior to this, outpatient treatment for ADHD in the US grew from 0.9 children per 100 in 1987 to 3.4 per 100 in 1997.[104] There is concern about the rising use of methylphenidate (Ritalin), mainly to treat ADHD and similar disorders, in the UK.[105] The incidence of ADHD is estimated at three to five percent of the population, while the number of children in the United States taking Ritalin is estimated at one to two percent.[106] In a small study of four American communities, the reported incidence of ADHD varied from 1.6% to 9.4%. The study also found that only 12.5% of the children reportedly meeting the DSM-III-R ADHD criteria for ADHD had been treated with stimulants during the past year.[107]

Stimulant misuse

There is non-medical prescription stimulant use. A 2003 study found that non prescription use by college students in the US was 6.9% with 4.1% using them within the last year.[108] A 2006 study with teens in Grades 7 to Grade 12 found that 2% reported non-medical use of prescription stimulant medication in the past 12 months, with 2% also reporting non-medical use of prescribed sedatives/and or anxiety medications, 3% using sleeping medications, and 12% reporting non-medical use of prescribed pain medications.[109]

Medication in preschoolers

Parents of children with ADHD note that they usually display their symptoms at an early age. Dr. John Van Brakle has stated, "pediatricians have long questioned whether such children can accurately be identified, given the overlap with normal behaviors in young children."[110] The use of stimulant medication has not been approved by the FDA for children under the age of six.[111] A growing trend is the diagnosis of younger children with ADHD. Prescriptions for children under the age of 5 rose nearly 50 percent from 2000 to 2003.[112] Research on this issue has indicated that stimulant medication can help younger children with "severe ADHD symptoms" but typically at a lower dose then older children. It was also found that children at this age are more sensitive to side effects and should be closely monitored.[111] Manos states, "it is prudent for physicians to be cautious," with medications. Evidence suggests that careful assessment and highly individualized behavioural interventions significantly improve both social and academic skills while medication only treats the symptoms of the disorder.[110] Manos suggests that, "one of the primary reasons cited for the growing use of psychotropic interventions was that many physicians realize that psychological interventions are costly and difficult to sustain."[113]

Adverse effects

A number of possible side effects are of concern with respect to ADHD medications.

Growth Delay and Weight Loss

The stunting of growth in children has been a concern. Past studies suggested that "long-term use of the drugs could stunt children's growth."[114] However, more recent studies suggest that children eventually do reach normal height and weight. According to Wilens (2004), treated children with ADHD tend to grow at a slower rate but catch up during adolescence and adulthood.[115] One notion is that psychostimulant medication can decrease appetite which may result in loss of weight and may be a factor in stunted growth.

Cardiovascular side effects

There is concern that stimulants and Atomoxetine, which increase the heart rate and blood pressure, might cause serious cardiovascular problems.[116]

In 2007 the FDA requires all ADHD drug manufacturers to notify patients about serious cardiovascular side effects. This was due to reports of sudden death in children taking these medications who had underlying heart problems and of high risk adults who suffered heart attacks and strokes.[117]

Studies indicated that, "the rate of sudden death of children taking ADHD medications do not appear to exceed the base rate of sudden death in the general population". Matthew Smith is purported to have died at age 14 after long-term use of Ritalin. The medical examiner determined that Smith died from Ritalin usage, but medical experts dispute this. The examiner also argued that it was likely that diabetic children were at higher risk for cardiac problems.[118]

Psychiatric side effects

In 2006 the FDA examined the occurrence of psychiatric side effects in ADHD medication. They found increased rates of psychosis and or mania with all drug treatments examined, including: Concerta, Ritalin LA, d-MPH, Atomoxetine, Adderall XR, Modafinil, MTS, and Metadate.[20]

Sleep problems may occur.[119]

Many of these drugs are associated with physical and psychological dependence.[120]

Issues with long-term use of stimulant medication

The short term use of stimulant medication has been shown to be effective yet its long term effects are yet to be determined. The Multimodal Treatment Study of Children with ADHD study concluded that while drugs such as Ritalin and Concerta (a delayed release form of Ritalin) worked in the short term, there was no demonstrable improvement in children's behavior after three years of medication."[121]

While ADHD is associated with an increased risk of substance abuse, stimulant medications have been shown to reduce the risk of subsequent development of substance abuse.[122][123]

Long term use and schizophrenia and drug induced psychosis

Although the safety profile of short-term methylphenidate therapy in clinical trials has been well established, repeated use of psychostimulants such as methylphenidate is less clear. The long term effects of methylphenidate in drug addiction, withdrawalreactions, psychosis, depression, and pregnancy has received very little research and thus the long term effects of using stimulants for ADHD are largely unknown. There are no well defined withdrawal schedules for discontinuing long term use of stimulants.[124] Short term clinical trials have shown an incidence of psychosis of 0.1%.[125]Psychosis occurs more commonly as a result of chronic use effecting about 6% of children on long term methylphenidate.[126] The long term effects on mental health disorders in later life of chronic use of methylphenidate is unknown.[127]Concerns have been raised that long-term therapy might cause drug dependence, paranoia, schizophrenia and behavioral sensitisation, similar to other stimulants.[128]Psychotic symptoms from methylphenidate can include, hearing voices, visual hallucinations, urges to harm oneself, severeanxiety, euphoria, grandiosity, paranoid delusions, confusion, increased aggression and irritability.Methylphenidate psychosis is unpredictable in who it will occur. Family history of mental illness does not predict the incidence of stimulant toxicosis in ADHD children. High rates of childhood stimulant use are found in ADHD patients who will eventually be diagnosed with comorbid schizophrenia and bipolar disorder. Individuals with a diagnosis of bipolar or schizophrenia who were prescribed stimulants during childhood typically have a significantly earlier onset of the psychotic disorder and suffer a more severe clinical course of psychotic disorder.[129][130][131]

Stimulant withdrawal and rebound effects

Stimulant withdrawal or rebound reactions can occur and should be minimised in intensity, i.e. via a gradual tapering off of medication over a period of weeks or months.[132][133][134] A very small study of abrupt withdrawal of stimulants did suggest that withdrawal reactions are not typical. Nonetheless withdrawal reactions may still occur in susceptible individuals.[135]The withdrawal or rebound symptoms of methylphenidate can include psychosis, irritability and depression and a return of ADHD symptoms in an exaggerated form. Methylphenidate may be worse for causing rebound and withdrawal effects due to its very short half life. Amphetamine may cause less severe rebound or withdrawal effects due to its somewhat longer half life.[77][136][137]Up to a third of ADHD children experience a rebound effect in ADHD symptoms when the methylphenidate dose wears off.[138]

Cancer

Concerns about chromosomal aberrations and possible cancer later in life was raised by a small-scale study on the use of methylphenidate, though a review by the Food and Drug Administration (FDA) found significant methodological problems with the study.[139] A follow-up study performed with improved methodology found no evidence that methylphenidate might cause cancer, stating "the concern regarding a potential increase in the risk of developing cancer later in life after long-term MPH treatment is not supported."[140]

Cost effectiveness

Combined medical management and behavioral treatment is the most effective ADHD management strategy, followed by medication alone, and then behavioral treatment.[1] In terms of cost-effectiveness, management with medication has been shown to be the most cost-effective, followed by behavioral treatment, and combined treatment.[1] The individually most effective and cost efficient way is with stimulant medication. Additionally, long-acting medications for ADHD, in comparison to short-acting varieties, generally seem to be cost effective.[141]Comorbid (relating to two diseases that occur together, e.g. depression and ADHD) disorders make finding the right treatment and diagnosis much more costly than when comorbid disorders are absent.

History

The first reported evidence of stimulant medication used to treat children with concentration and hyperactivity problems came in 1937.[142] Dr. Charles Bradley in Providence, Rhode Island reported that a group of children with behavioral problems improved after being treated with the stimulantBenzedrine.[143] In 1957, the stimulant methylphenidate (Ritalin, which was first produced in 1950) became available under various names (including Focalin, Concerta, Metadate, and Methylin); it remains one of the most widely prescribed medications for ADHD. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the 1960s and steadily rose in use.

In 1975, pemoline (Cylert) was approved by the U.S. FDA for use in the treatment of ADHD. While an effective agent for managing the symptoms, the development of liver failure in 14 cases over the next 27 years would result in the manufacturer withdrawing this medication from the market. New delivery systems for medications were invented in 1999 that eliminated the need for multiple doses across the day or taking medication at school. These new systems include pellets of medication coated with various time-release substances to permit medications to dissolve hourly across an 8–12 hour period (Metadate CD, Adderall XR, Focalin XR) and an osmotic pump that extrudes a liquid methylphenidate sludge across an 8–12 hour period after ingestion (Concerta).

In 2003, atomoxetine (Strattera) received the first FDA approval for a nonstimulant drug to be used specifically for ADHD. In 2007, lisdexamfetamine (Vyvanse) becomes the first prodrug to receive FDA approval for ADHD.

In 1999 the largest study of treatment for ADHD was published in the American Journal of Psychiatry. Known as the Multimodal Treatment Study of ADHD (MTA Study), it involved more than 570 children with ADHD at 6 sites in the United States and Canada randomly assigned to 4 treatment groups. All 4 treatment groups showed marked improvement from the time of baseline measurements to completion of the study 14 months later. Behavioral treatment was as effective as medication alone on 16 of 19 outcome measures.[18] This was especially good for the behavior modification group, since the behavioral protocols were faded 3 months prior to the last evaluation and the stimulant group continued to receive medication right up to the last evaluation point.[2]

Alternative medicine

See also: Alternative therapies for developmental and learning disabilities

Some proponents of alternative medicine advocate that alternative therapies may be tried before ADHD medications, although not all ADHD children will have any effective response.[77]

Some people report short-term positive results using medical cannabis for treating ADHD and doctor David Bearman supported this treatment.[144][145] However, long-term effects of cannabis use can include substance dependence, drug tolerance, increase risk for schizophrenia, bipolar disorders, and major depression.[146][147][148]

Biofeedback

EEG biofeedback is a treatment strategy used for children, adolescents and adults with ADHD.[149] EEG biofeedback, also sometimes referred to as neurofeedback, is effective in treating attention, impulsivity and hyperactivity. There are no known side effects from biofeedback therapy although research into biofeedback has been limited and further research has been recommended.[150] One 2009 study concluded "that NF may be considered as a clinically effective module in the treatment of children with ADHD"[151] The human brain emits electrical energy which is measured with electrodes on the brain. Biofeedback alerts the patient when beta waves are present. This theory believes that those with ADHD can train themselves to decrease ADHD symptoms. There is a distinct split in the scientific community about the effectiveness of the treatment. A number of studies indicate the scientific evidence has been increasing in recent years for the effectiveness of EEG biofeedback for the treatment of ADHD. According to a 2007 review, the effectiveness of the treatment was demonstrated to be equivalent to that of stimulant medication. The review noted that improvements are seen at the behavioral and neuropsychological level with the symptoms of inattention, hyperactivity and impulsivity, showing significant decreases after treatment. There are no known side effects from EEG biofeedback therapy. There are methodological limitations and weaknesses in study designs however. In a 2005 review, Loo and Barkley stated that problems including lack of blinding such as placebo control and randomization are significant limitations to the studies into EEG biofeedback and make definitive conclusions impossible to make.[152] As a result more robust clinical studies have been strongly recommended.[153] A German review in 2004 found that EEG biofeedback, also sometimes referred to as neurofeedback, is more effective than previously thought in treating attention deficiency, impulsivity and hyperactivity; short-term effects match those of stimulant treatment, and a persistent normalization of EEG parameters is found even after treatment--this is not found after treatment with stimulants.[154] There are no known side effects from biofeedback therapy although research into biofeedback has been limited and further research has been recommended.[154] An American review the following year also emphasized the benefits of this method.[155] Similar findings were reported in a study by another German team in 2004.[156]

Aerobic fitness

Aerobic fitness may improve cognitive functioning and neural organization related to executive control during pre-adolescent development, though more studies are needed in this area.[157] One study suggests that athletic performance in boys with ADHD may increase peer acceptance when accompanied by fewer negative behaviors.[158]

Massage Therapy

For children and adolescents with ADHD, pediatric massage therapy has been found to improve mood and increase on-task behaviors, while reducing anxiety and hyperactivity.[159][160]

Art Therapy

Art is thought by some to be an effective therapy for some of the symptoms of ADHD. Other sources, including some psychologists who have written on the subject, feel that cutting down on time spent on television, video games, or violent media can help some children. One study indicated a correlation between excessive TV time as a child with higher rates of ADHD symptoms.[161] Other therapies that have been effective for some have been ADHD coaching, positive changes in diet, such as low sugar, low additives, and no caffeine. Children who spend time outdoors in natural settings, such as parks, seem to display fewer symptoms of ADHD, which has been dubbed "Green Therapy".[162]

Dietary supplements

Dietary supplements and specialized diets are sometimes used by people with ADHD with the intent to mitigate some or all of the symptoms. For example, Omega-3 supplementation (seal, fish or krill oil) may reduce ADHD symptoms for a subgroup of children and adolescents with ADHD "characterized by inattention and associated neurodevelopmental disorders."[163] Although vitamin or mineral supplements (micronutrients) may help children diagnosed with particular deficiencies, there is no evidence that they are helpful for all children with ADHD. Furthermore, megadoses of vitamins, which can be toxic, must be avoided.[164] In the United States, no dietary supplement has been approved for the treatment for ADHD by the FDA.[165] There is however a pilot study done which shows that phosphatidyl serine (PS) can help against ADHD.[166]

Some popular supplements used to manage ADHD symptoms:

Diets

Perhaps the best known of the dietary alternatives is the Feingold diet which involves removing salicylates, artificial colors and flavors, and certain synthetic preservatives from children's diets.[179] However, studies have shown little if any effect of the Feingold diet on the behavior of children with ADHD.[180]

A meta-analysis has found that dietary elimination of artificial food coloring and preservatives provides a statistically significant benefit in children with ADHD.[181] Other more recent studies agree with these conclusions.[182][183] The UK Food Standards Agency (FSA) has called for a ban on the use of six artificial food colorings[184] and the European Union (EU) has ruled that some food dyes must be labeled with the relevant E number as well as this warning: "may have an adverse effect on activity and attention in children."[185]

Comorbid disorders

Because ADHD comorbidities are diverse and the rate of comorbidity is high, special care must dedicated to certain comorbidities. The FDA is not set up to address this issue, and does not approve medications for comorbidities, nonetheless certain such topics have been extensively researched.

Tic disorders

Patients with Tourette syndrome who are referred to specialty clinics have a high rate of comorbid ADHD. Patients who have ADHD along with tics or tic disorders may also have problems with disruptive behaviors, overall functioning, and cognitive function, accounted for by the comorbid ADHD.[186]

The treatment of ADHD in the presence of tic disorders has long been a controversial topic. Past medical practice held that stimulants (such as Ritalin) could not be used in the presence of tics, due to concern that their use might worsen tics;[187] however, multiple lines of research have shown that stimulants can be cautiously used in the presence of tic disorders.[188] Several studies have shown that stimulants do not exacerbate tics any more than placebo does, and suggest that stimulants may even reduce tic severity.[189] Controversy remains, and the PDR continues to carry a warning that stimulants should not be used in the presence of tic disorders, so physicians may be reluctant to use them. Others are comfortable using them and even advocate for a stimulant trial when ADHD co-occurs with tics, because the symptoms of ADHD can be more impairing than tics.[187][190]

The stimulants are the first line of treatment for ADHD, with proven efficacy, but they do fail in up to 20% of cases, even in patients without tic disorders.[191] Current prescribed stimulant medications include: methylphenidate (brand names Ritalin, Metadate, Concerta), dextroamphetamine (Dexedrine), and mixed amphetamine salts (Adderall). Other medications can be used when stimulants are not an option. These include the alpha-2 agonists (clonidine and guanfacine), tricyclic antidepressants (desipramine and nortriptyline), and newer antidepressants (bupropion and venlafaxine. There have been case reports of tics worsening with bupropion (brand name Wellbutrin). There is good empirical evidence for short-term safety and efficacy for the use of desipramine, bupropion and atomoxetine (Strattera).[191]

References

  1. ^ a b c d Jensen, et al.; Garcia, JA; Glied, S; Crowe, M; Foster, M; Schlander, M; Hinshaw, S; Vitiello, B et al. (2005). "Cost-Effectiveness of ADHD Treatments: Findings from the Multimodal Treatment Study of Children With ADHD". American Journal of Psychiatry 162 (9): 1628–1636 (Page:1633). doi:10.1176/appi.ajp.162.9.1628. PMID 16135621.  Free full text
  2. ^ a b Arnold, L.E.; Chuang, S.; Davies, M.; Abikoff, H.B; Conners, C.K.; Elliott, G.R.; Greenhill, L.L.; Hechtman, L. et al. (2004). "Nine Months of Multicomponent Behavioral Treatment for ADHD and Effectiveness of MTA Fading Procedures". Journal of Abnormal Child Psychology 32 (1): 39–51. doi:10.1023/B:JACP.0000007579.61289.31. PMID 14998110. 
  3. ^ http://www.nimh.nih.gov/science-news/2009/short-term-intensive-treatment-not-likely-to-improve-long-term-outcomes-for-children-with-adhd.shtml
  4. ^ Molina, BS; Hinshaw, SP; Swanson, JM; Arnold, LE; Vitiello, B; Jensen, PS; Epstein, JN; Hoza, B et al. (2009). "The MTA at 8 years: Prospective follow-up of children treated for combined type ADHD in the multisite study". Journal of the American Academy of Child and Adolescent Psychiatry 48 (5): 484–500. doi:10.1097/CHI.0b013e31819c23d0. PMC 3063150. PMID 19318991. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3063150. 
  5. ^ Rabbani, A; Alexander GC (December 2009). "Impact of family structure on stimulant use among children with attention-deficit/hyperactivity disorder". Health Services Research 44 (6): 2060–2078. doi:10.1111/j.1475-6773.2009.01019.x. PMC 2796314. PMID 19732168. http://www.ncbi.nlm.nih.gov/pubmed?term=19732168. Retrieved 11/10/2011. 
  6. ^ Stephen V. Faraone, P. (2003, September 18). Retrieved from Medscape Today: http://www.medscape.com/viewarticle/461543
  7. ^ "Atomoxetine (marketed as Strattera) Information". http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107912.htm. Retrieved 12 July 2009. 
  8. ^ a b Stein MA (July 2004). "Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments". Am J Manag Care 10 (4 Suppl): S89–98. PMID 15352535. http://www.ajmc.com/supplement/managed-care/2004/2004-07-vol10-n4Suppl/Jul04-1821pS089-S098. 
  9. ^ a b Christman AK, Fermo JD, Markowitz JS (August 2004). "Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder". Pharmacotherapy 24 (8): 1020–36. doi:10.1592/phco.24.11.1020.36146. PMID 15338851. 
  10. ^ a b Hazell P (October 2005). "Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?". Expert Opin Pharmacother 6 (12): 1989–98. doi:10.1517/14656566.6.12.1989. PMID 16197353. http://www.informapharmascience.com/doi/abs/10.1517/14656566.6.12.1989. 
  11. ^ a b c d e f American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. (October 2001). "Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder". Pediatrics 108 (4): 1033–44. doi:10.1542/peds.108.4.1033. PMID 11581465. http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=11581465. 
  12. ^ Bloh, C. (2010). "Assessing Self-Control Training in Children with Attention Deficit Hyperactivity Disorder". The Behavior Analyst Today 10: 357–363. http://findarticles.com/p/articles/mi_6884/is_3-4_10/ai_n56218058/. 
  13. ^ Barry, Leasha M.; Haraway, Dana L. (2005). "Self-Management and ADHD: A Literature Review". The Behavior Analyst Today 6 (1): 48–53. http://findarticles.com/p/articles/mi_6884/is_1_6/ai_n28321089/. 
  14. ^ Fabianoa, G.A.; Pelham, W.E. Jr.; Colesb, E.K.; Gnagya, E.M.; Chronis-Tuscanoc, A.; O'Connora, B.C. (2008). "A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder". Clinical Psychology Review 29 (2): 129–140. doi:10.1016/j.cpr.2008.11.001. PMID 19131150. 
  15. ^ King S, Griffin S, Hodges Z, et al. (July 2006). "A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents". Health Technol Assess 10 (23): iii–iv, xiii–146. PMID 16796929. http://www.hta.ac.uk/execsumm/summ1023.htm. 
  16. ^ Murphy, Kevin R.; Barkley, Russell A. (2005). Attention-Deficit Hyperactivity Disorder, Third Edition : A Clinical Workbook. New York: The Guilford Press. ISBN 1-59385-227-4. http://books.google.com/?id=EkyTTvjNRZAC&pg=PA626&lpg=PA626&dq=long+term+safety+of+stimulants#PPA626,M1. 
  17. ^ a b Lerner M, Wigal T (January 2008). "Long-term safety of stimulant medications used to treat children with ADHD". Pediatric annals 37 (1): 37–45. doi:10.3928/00904481-20080101-11. PMID 18240852. 
  18. ^ a b c Stern HP, Stern TP (September 2002). "When children with attention-deficit/hyperactivity disorder become adults". South. Med. J. 95 (9): 985–91. PMID 12356139. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=95&issue=9&spage=985. 
  19. ^ "CG72 Attention deficit hyperactivity disorder (ADHD): full guideline" (PDF). NHS. 24 September 2008. http://www.nice.org.uk/nicemedia/pdf/CG72FullGuideline.pdf. Retrieved 2008-10-08. 
  20. ^ a b "www.fda.gov" (PDF). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_10_01_Mosholder.pdf. 
  21. ^ Greydanus DE, Pratt HD, Patel DR (February 2007). "Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult". Dis Mon 53 (2): 70–131. doi:10.1016/j.disamonth.2007.01.001. PMID 17386306. http://linkinghub.elsevier.com/retrieve/pii/S0011-5029(07)00002-8. 
  22. ^ Schlamp D (March 2007). "[My child is so restless]" (in German). MMW Fortschr Med 149 (10): 39–40. PMID 17408047. 
  23. ^ "Update on drugs for hyperactivity in childhood". Drug Ther Bull 45 (5): 37–40. May 2007. doi:10.1136/dtb.2007.45537. PMID 17536494. 
  24. ^ Barkley, R. (2005) Take Charge of ADHD: The Complete Authoritative Guide for Parents NY: Guilford Publications
  25. ^ Kazdin, Alan E. Parent management training : treatment for oppositional, aggressive, and antisocial behavior in children and adolescents. Oxford University Press, 2005
  26. ^ Klingberg, T.; Fernell, E.; Olesen, P.J.; Johnson, M.; Gustafsson, P.; Dahlstrom, K.; Gillberg, Christopher G; Forssberg, Hans et al. (2005). "Computerized training of working memory in children with ADHD--A randomized, controlled trial". Journal of the American Academy of Child & Adolescent Psychiatry 44 (2): 177–186. doi:10.1097/00004583-200502000-00010. PMID 15689731. 
  27. ^ Stephen V. Faraone, P. (2003, September 18). Retrieved from Medscape Today:Medscape.com
  28. ^ Sulzer D, Sonders MS, Poulsen NW, Galli A (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". Progress in Neurobiology 75 (6): 406–33. doi:10.1016/j.pneurobio.2005.04.003. PMID 15955613. 
  29. ^ National Toxicology, Program (July 2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines". Ntp Cerhr Mon (16): vii–III1. PMID 16130031. 
  30. ^ Howland RH (August 2008). "Lisdexamfetamine: a prodrug stimulant for ADHD". Journal of Psychosocial Nursing and Mental Health Services 46 (8): 19–22. PMID 18777964. 
  31. ^ "Ritalin Abuse, Addiction and Treatment". http://www.addictionsearch.com/treatment_articles/article/ritalin-abuse-addiction-and-treatment_43.html. 
  32. ^ "Dopamine". http://www.iscid.org/encyclopedia/Dopamine. 
  33. ^ "Treatment of ADHD When Tolerance to Methylphenidate Develops". http://psychservices.psychiatryonline.org/cgi/content/full/53/1/102. 
  34. ^ "Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children". http://www.nature.com/clpt/journal/v66/n3/abs/clpt1999454a.html. 
  35. ^ "Methylphenidate". http://www.teenoverthecounterdrugabuse.com/methylphenidate.html. 
  36. ^ Solanto MV (July 1998). "Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration". Behavioural Brain Research 94 (1): 127–52. doi:10.1016/S0166-4328(97)00175-7. PMID 9708845. 
  37. ^ Schachter HM, Pham B, King J, Langford S, Moher D (November 2001). "How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis". CMAJ 165 (11): 1475–88. PMC 81663. PMID 11762571. http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=11762571. 
  38. ^ Ross RG (July 2006). "Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder". The American Journal of Psychiatry 163 (7): 1149–52. doi:10.1176/appi.ajp.163.7.1149. PMID 16816217. 
  39. ^ a b "Ritalin Addiction". http://www.drug-rehabs.org/drugs/ritalin.php. 
  40. ^ "The truth about North America’s greatest drug problem: Ritalin". http://www.laleva.cc/choice/ritalin.html. 
  41. ^ Wilens TE, Adler LA, Adams J (January 2008). "Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature". Journal of the American Academy of Child and Adolescent Psychiatry 47 (1): 21–31. doi:10.1097/chi.0b013e31815a56f1. PMID 18174822. 
  42. ^ Lerner M, Wigal T. Long-term safety of stimulant medications used to treat children with ADHD. Pediatr Ann. 2008 Jan;37(1):37-45.
  43. ^ Zhu J, Reith ME (November 2008). "Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse". CNS & Neurological Disorders Drug Targets 7 (5): 393–409. doi:10.2174/187152708786927877. PMC 3133725. PMID 19128199. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3133725. 
  44. ^ Faraone SV, Wilens T (2003). "Does stimulant treatment lead to substance use disorders?". J Clin Psychiatry 64 Suppl 11: 9–13. PMID 14529324. 
  45. ^ Faraone SV, Wilens TE (2007). "Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion". J Clin Psychiatry 68 Suppl 11: 15–22. PMID 18307377. 
  46. ^
  47. ^ "NIMH · ADHD · The Treatment of ADHD". http://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder/medications.shtml. 
  48. ^ King S, Griffin S, Hodges Z (July 2006). "A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents". Health Technology Assessment 10 (23): iii–iv, xiii–146. PMID 16796929. http://www.hta.ac.uk/execsumm/summ1023.htm. 
  49. ^ Murphy, Kevin R.; Barkley, Russell A. (2005). Attention-Deficit Hyperactivity Disorder, Third Edition : A Clinical Workbook. New York: The Guilford Press. ISBN 1-59385-227-4. http://books.google.com/?id=EkyTTvjNRZAC&pg=PA626&lpg=PA626&dq=long+term+safety+of+stimulants. 
  50. ^ "What is the evidence for using CNS stimulants to treat ADHD in children? | Therapeutics Initiative". http://www.ti.ubc.ca/letter69. 
  51. ^ Lerner M, Wigal T (January 2008). "Long-term safety of stimulant medications used to treat children with ADHD". Pediatric annals 37 (1): 37–45. doi:10.3928/00904481-20080101-11. PMID 18240852. 
  52. ^ "FDA News". Food and Drug Administration. February 21, 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108849.htm. Retrieved 2009-08-14. 
  53. ^ "Drugs with Black Box Warnings - Comprehensive List". FormWeb. Joyce Generali. 05-04-2009. http://www.formularyproductions.com/master/showpage.php?dir=blackbox&whichpage=9. Retrieved 2009-05-19. 
  54. ^ American Academy of Pediatrics/American Heart Association (August 2008). "American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008". Journal of Developmental and Behavioral Pediatrics 29 (4): 335. doi:10.1097/DBP.0b013e31318185dc14. PMID 18698199. 
  55. ^ Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA (May 2006). "A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study". The Journal of Clinical Psychiatry 67 (5): 727–35. doi:10.4088/JCP.v67n0506. PMID 16841622. http://article.psychiatrist.com/?ContentType=START&ID=10002551. 
  56. ^ Greenhill LL, Biederman J, Boellner SW (May 2006). "A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder". Journal of the American Academy of Child and Adolescent Psychiatry 45 (5): 503–11. doi:10.1097/01.chi.0000205709.63571.c9. PMID 16601402. 
  57. ^ "Modavigil Product Information". http://secure.healthlinks.net.au/content/csl/pi.cfm?product=cspmodav11207. Retrieved 2008-07-02. 
  58. ^ Schlander M (October 2007). "Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness". Eur Child Adolesc Psychiatry 16 (7): 421–9. doi:10.1007/s00787-007-0615-2. PMID 17401606. 
  59. ^ Weiss MD, Gadow K, Wasdell MB (2006). "Effectiveness outcomes in attention-deficit/hyperactivity disorder". J Clin Psychiatry 67 Suppl 8: 38–45. PMID 16961429. 
  60. ^ "Treatment of Attention-Deficit/Hyperactivity Disorder". http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.14677. 
  61. ^ Department of Health and Human Services Mental Health: A Report of the Surgeon GeneralPDF (1.01 MB) Page 142. Accessed 04/14/07
  62. ^ a b c Arnold (2000). "Methylphenidate vs Amphetamine: Comparative Review". Journal of Attention Disorders 3 (4): 200–211. doi:10.1177/108705470000300403. 
  63. ^ Rapoport JL, Inoff-Germain G (2002). "Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002". J Atten Disord 6 Suppl 1: S57–60. PMID 12685519. 
  64. ^ Dusan Kolar, Amanda Keller, Maria Golfinopoulos, Lucy Cumyn, Cassidy Syer, and Lily Hechtman (February 2008). "Treatment of adults with attention-deficit/hyperactivity disorder". Neuropsychiatr Dis Treat 4 (1): 107–121. PMC 2515906. PMID 18728812. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2515906. 
  65. ^ Spencer TJ. (April 2007). "Pharmacology of adult ADHD with stimulants.". CNS Spectr 12 (4(supplement 6)): 8–11. PMID 17715564. http://www.cnsspectrums.com/aspx/articledetail.aspx?articleid=1671. 
  66. ^ Rostain, Anthony L. (September 2008). "ADHD in Adults: Attention-Deficit/Hyperactivity Disorder in Adults: Evidence-Based Recommendations for Management". Postgraduate Medicine 120 (3): 27–38. doi:10.3810/pgm.2008.09.1905. PMID 18824823. http://www.postgradmed.com/index.php?art=pgm_09_2008?article=1905. 
  67. ^ Spencer, Thomas. Biederman, Joseph. Wilens, Timothy (June 2004). "Stimulant treatment of adult attention-deficit/hyperactivity disorder". Psychiatric Clinics of North America 27 (2). http://www.mdconsult.com/das/article/body/138353191-2/jorg=journal&source=&sp=14616830&sid=0/N/410882/1.html?issn=0193-953X. 
  68. ^ Higgins ES (January 1999). "A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder". J Fam Pract 48 (1): 15–20. PMID 9934377. 
  69. ^ Verbeeck W, Tuinier S, Bekkering GE. (February 2009). "Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review.". Adv Ther 26 (2): 170–184. doi:10.1007/s12325-009-0008-7. PMID 19238340. http://www.springerlink.com/content/ph82718338384515/fulltext.pdf. 
  70. ^ Vendantam, Shankar. "Debate Over Drugs For ADHD Reignites." The Washington Post 27 Mar. 2009. 2009. Web. 2 Mar. 2010.
  71. ^ National Toxicology, Program (July 2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines". Ntp Cerhr Mon (16): vii–III1. PMID 16130031. 
  72. ^ a b Glaser, et al.; Thomas, TC; Joyce, BM; Castellanos, FX; Gerhardt, GA (2005). "Differential Effects of Amphetamine Isomers on Dopamine in the Rat Striatum and Nucleus Accumbens Core". Psychopharmacology 178 (2-3): 250–258 (Page: 255). doi:10.1007/s00213-004-2012-6. PMID 15719230. 
  73. ^ Schepers RJ et al. (2003). "Methamphetamine and Amphetamine Pharmacokinetics in Oral Fluid and Plasma after Controlled Oral Methamphetamine Administration to Human Volunteers". Clin Chemistry 49 (1): 121–132 (Pages:121,130). doi:10.1373/49.1.121. PMID 12507968.  Free full text
  74. ^ Shoblock, et al.; Sullivan, EB; Maisonneuve, IM; Glick, SD (2003). "Neurochemical and Behavioral Differences Between D-Methamphetamine and D-Amphetamine in Rats". Psychopharmacology 165 (4): 359–369 (Page:366). doi:10.1007/s00213-002-1288-7. PMID 12491026. 
  75. ^ Williams, C. Donald (1996-04-21). "Methamphetamine for ADHD". Psychopharmacology Tips. http://www.dr-bob.org/tips/split/Methamphetamine-for-ADHD.html. Retrieved 2007-04-15. 
  76. ^ Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". CNS Drugs 20 (9): 713–738 (Page:730). doi:10.2165/00023210-200620090-00002. PMID 16953648. 
  77. ^ a b c Kidd PM (2000). "Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management" (PDF). Altern Med Rev 5 (5): 402–28. PMID 11056411. http://www.thorne.com/altmedrev/.fulltext/5/5/402.pdf. 
  78. ^ Zhu J, Reith ME (2008). "Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse". CNS & Neurological Disorders Drug Targets 7 (5): 393–409. doi:10.2174/187152708786927877. PMC 3133725. PMID 19128199. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3133725. 
  79. ^ Stein MA (July 2004). "Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments". The American Journal of Managed Care 10 (4 Suppl): S89–98. PMID 15352535. http://www.ajmc.com/pubMed.php?pii=2632. 
  80. ^ Christman AK, Fermo JD, Markowitz JS (August 2004). "Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder". Pharmacotherapy 24 (8): 1020–36. doi:10.1592/phco.24.11.1020.36146. PMID 15338851. 
  81. ^ Hazell P (October 2005). "Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?". Expert Opinion on Pharmacotherapy 6 (12): 1989–98. doi:10.1517/14656566.6.12.1989. PMID 16197353. 
  82. ^ "Atomoxetine (marketed as Strattera) Information". http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107912.htm. Retrieved 12 July 2009. 
  83. ^ Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW et al. (December 2005). "Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.". Neurology 65 (12): 1941–9. doi:10.1212/01.wnl.0000188869.58300.a7. PMID 16380617. 
  84. ^ Arnsten AF. The use of alpha-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother. 10:1595-605, 2010
  85. ^ "Atomoxetine (marketed as Strattera) Information". http://www.fda.gov/CDER/drug/infopage/atomoxetine/default.htm. 
  86. ^ Lakhan, SE; Hagger-Johnson, G. (2007). "The impact of prescribed psychotropics on youth". Clinical Practice and Epidemiology in Mental Health 3 (1): 21. doi:10.1186/1745-0179-3-21. PMC 2100041. PMID 17949504. http://www.cpementalhealth.com/content/3/1/21. 
  87. ^ Hallowell, Edward M.; John J. Ratey (2005). Delivered from Distraction : Getting the Most out of Life with Attention Deficit Disorder. [New York: Ballantine Books. pp. 253–5. ISBN 0-345-44231-8. 
  88. ^ Wellbutrin: Prescribing InformationPDF (170 KB). GlaxoSmithKline (September 2006). Retrieved on 2007-04-15.
  89. ^ Stahl S, Pradko J, Haight B, Modell J, Rockett C, Learned-Coughlin S (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Prim Care Companion J Clin Psychiatry 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842. PMID 15361919. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=514842.  Full text at PMC: 514842
  90. ^ Frazin, Natalie (2002-04-02). "Methylphenidate and Clonidine Help Children With ADHD and Tics". National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/news_and_events/news_articles/news_article_adhd.htm. Retrieved 2007-04-15. 
  91. ^ Kako, Yuki; Niwa, Y; Toyomaki, A; Yamanaka, H; Kitagawa, N; Denda, K; Koyama, T (April 2007). "A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran". Progress in Neuro-Psychopharmacology & Biological Psychiatry 31 (3): 772–775. doi:10.1016/j.pnpbp.2006.12.017. ISSN 0278-5846. PMID 17300859. 
  92. ^ Kumar R (2008). "Approved and investigational uses of modafinil : an evidence-based review". Drugs 68 (13): 1803–39. doi:10.2165/00003495-200868130-00003. PMID 18729534. 
  93. ^ Toren P, Ratner S, Weizman A, Lask M, Ben-Amitay G, Laor N. Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up study. Journal of Child and Adolescent Psychopharmacology. 2007 Dec;17(6):803-12. PMID 18315452
  94. ^ - Florida Medicaid To Review Antipsychotics & ADHD
  95. ^ "Atypical Antipsychotics for Treatment of Schizophrenia Spectrum Disorders". http://www.psychiatrictimes.com/schizophrenia/content/article/10168/1147536. 
  96. ^ Physicians Postgraduate Press, Inc., Dosing of Atypical Antipsychotics in Children and Adolescents
  97. ^ of Public Health, Guidelines for the use of atypical antipsychotics in adults
  98. ^ NIMH · ADHD · The Treatment of ADHD
  99. ^ Lakhan SE; Hagger-Johnson G. http://www.cpementalhealth.com/content/3/1/21 The impact of prescribed psychotropics on youth. Clinical Practice and Epidemiology in Mental Health 2007;3(21).
  100. ^ &Na;, (August 2008). "American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008". J Dev Behav Pediatr 29 (4): 335. doi:10.1097/DBP.0b013e31318185dc14. PMID 18698199. http://circ.ahajournals.org/cgi/content/full/117/18/2407. 
  101. ^ http://psych.umb.edu/faculty/adams/fall%202006/MTA%20-%20growth.pdf
  102. ^ http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B987N-4XKH91T-F&_user=10&_coverDate=08%2F31%2F2007&_rdoc=13&_fmt=high&_orig=browse&_srch=doc-info(%23toc%2359159%232007%23999539991%231550322%23FLA%23display%23Volume&_cdi=59159&_sort=d&_docanchor=&_ct=21&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=8b46dfb4260165bb2a3051e581263cd4
  103. ^ http://www.nimh.nih.gov/press/adhdmedsuse.cfm "ADHD Medication Use Held Steady in Recent Years" April 2006
  104. ^ Name, LM; Olfson, M; Gameroff, MJ; Marcus, SC; Jensen, PS. (2003). "National trends in the treatment of attention deficit hyperactivity disorder". American Journal of Psychiatry 160 (6): 1071–1077. doi:10.1176/appi.ajp.160.6.1071. PMID 10326176. 
  105. ^ "Sharp rise in children's Ritalin use". BBC News. 2003-07-19. http://news.bbc.co.uk/1/hi/health/3072445.stm. Retrieved 2010-04-25. 
  106. ^ http://www.gladwell.com/1999/1999_02_02_a_ritalin.htm Running from Ritalin".
  107. ^ http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10405496&query_hl=6&itool=pubmed_docsum Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. Journal of the American Academy of Child and Adolescent Psychiatry 38 (7):797-804.
  108. ^ McCabe SE, Knight JR, Teter CJ, Wechsler H (January 2005). "Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey". Addiction (Abingdon, England) 100 (1): 96–106. doi:10.1111/j.1360-0443.2005.00944.x. PMID 15598197. 
  109. ^ Boyd CJ, McCabe SE, Cranford JA, Young A (December 2006). "Adolescents' motivations to abuse prescription medications". Pediatrics 118 (6): 2472–2480. doi:10.1542/peds.2006-1644. PMC 1785364. PMID 17142533. http://pediatrics.aappublications.org/cgi/content/full/118/6/2472. 
  110. ^ a b Nonmedicinal Treatment Touted For Preschoolers With ADHD
  111. ^ a b Preschoolers With ADHD Improve With Low Doses Of Medication
  112. ^ Freudenheim, Milt (2004-05-17). "Behavior Drugs Lead in Sales For Children". The New York Times. http://query.nytimes.com/gst/fullpage.html?res=9C0DEEDF143FF934A25756C0A9629C8B63. Retrieved 2010-04-25. 
  113. ^ http://www.medscape.com/viewarticle/523542
  114. ^ "Questions over drugs for ADHD". BBC News. 2007-11-12. http://news.bbc.co.uk/2/hi/uk_news/7090011.stm. Retrieved 2010-04-25. 
  115. ^ Wilens, T.E. (2004) Straight Talk About Medications For Kids. NY: The Guilford Press.
  116. ^ "www.fda.gov" (PDF). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_06_01_Gelperin.pdf. 
  117. ^ "FDA News". FDA. February 21, 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108849.htm. Retrieved 2009-08-14. 
  118. ^ "Questions Raised Over Ritalin". CBS News. 2000-04-18. http://www.cbsnews.com/stories/2000/04/18/national/main185425.shtml. 
  119. ^ Silver, Larry M.D. ADHD Medications: Say No to Side Effects,ADDitude magazine, February 2006.
  120. ^ "www.fda.gov" (PDF). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_16_01_ADHD%20Drug%20Labels.pdf. 
  121. ^ "Report: ADHD Drugs May Stunt Growth, Long-Term Effectiveness Unknown". Fox News. 2007-11-12. http://www.foxnews.com/story/0,2933,310596,00.html. 
  122. ^ Faraone SV, Wilens TE (2007). "Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion". J Clin Psychiatry 68 Suppl 11: 15–22. PMID 18307377. 
  123. ^ Wilens TE, Faraone SV, Biederman J, Gunawardene S (January 2003). "Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature". Pediatrics 111 (1): 179–85. doi:10.1542/peds.111.1.179. PMID 12509574. 
  124. ^ Ashton H, Gallagher P, Moore B (September 2006). "The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder". J. Psychopharmacol. (Oxford) 20 (5): 602–10. doi:10.1177/0269881106061710. PMID 16478756. http://jop.sagepub.com/cgi/pmidlookup?view=long&pmid=16478756. 
  125. ^ "Ritalin & Ritalin-SR Prescribing Information" (PDF). Novartis. April 2007. http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf. 
  126. ^ Cherland E, Fitzpatrick R (October 1999). "Psychotic side effects of psychostimulants: a 5-year review". Can J Psychiatry 44 (8): 811–3. PMID 10566114. 
  127. ^ Kimko HC, Cross JT, Abernethy DR (December 1999). "Pharmacokinetics and clinical effectiveness of methylphenidate". Clin Pharmacokinet 37 (6): 457–70. doi:10.2165/00003088-199937060-00002. PMID 10628897. 
  128. ^ Dafny N; Yang PB. (15). "The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: A review of its locomotor effects.". Brain research bulletin. 68 (6): 393–405. doi:10.1016/j.brainresbull.2005.10.005. PMID 16459193. 
  129. ^ Ross RG (July 2006). "Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder". Am J Psychiatry 163 (7): 1149–52. doi:10.1176/appi.ajp.163.7.1149. PMID 16816217. http://ajp.psychiatryonline.org/cgi/content/full/163/7/1149. 
  130. ^ DelBello MP, Soutullo CA, Hendricks W, Niemeier RT, McElroy SL, Strakowski SM (April 2001). "Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset". Bipolar Disord 3 (2): 53–7. doi:10.1034/j.1399-5618.2001.030201.x. PMID 11333062. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1398-5647&date=2001&volume=3&issue=2&spage=53. 
  131. ^ Soutullo CA, DelBello MP, Ochsner JE, et al. (August 2002). "Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment". J Affect Disord 70 (3): 323–7. doi:10.1016/S0165-0327(01)00336-6. PMID 12128245. http://linkinghub.elsevier.com/retrieve/pii/S0165032701003366. 
  132. ^ Cohen D, Leo J, Stanton T, et al. (2002). "A boy who stops taking stimulants for "ADHD": commentaries on a Pediatrics case study". Ethical Hum Sci Serv 4 (3): 189–209. PMID 15278983. 
  133. ^ Schwartz RH, Rushton HG (May 2004). "Stuttering priapism associated with withdrawal from sustained-release methylphenidate". J. Pediatr. 144 (5): 675–6. doi:10.1016/j.jpeds.2003.12.039. PMID 15127013. http://linkinghub.elsevier.com/retrieve/pii/S0022347604000228. 
  134. ^ Garland EJ (1998). "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats". J. Psychopharmacol. (Oxford) 12 (4): 385–95. doi:10.1177/026988119801200410. PMID 10065914. 
  135. ^ Nolan EE, Gadow KD, Sprafkin J (April 1999). "Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder". Pediatrics 103 (4 Pt 1): 730–7. doi:10.1542/peds.103.4.730. PMID 10103294. 
  136. ^ Rosenfeld AA (February 1979). "Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report". Am J Psychiatry 136 (2): 226–8. PMID 760559. http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=760559. 
  137. ^ Smucker WD, Hedayat M (September 2001). "Evaluation and treatment of ADHD". Am Fam Physician 64 (5): 817–29. PMID 11563573. http://www.aafp.org/afp/20010901/817.htmlAdding. 
  138. ^ Riccio CA, Waldrop JJ, Reynolds CR, Lowe P (2001). "Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation". J Neuropsychiatry Clin Neurosci 13 (3): 326–35. doi:10.1176/appi.neuropsych.13.3.326. PMID 11514638. http://neuro.psychiatryonline.org/cgi/content/full/13/3/326. 
  139. ^ Ackerman, Todd (1 July 2005). "Closer look for possible Ritalin, cancer link". Houston Chronicle. http://www.chron.com/disp/story.mpl/front/3250025.html. Retrieved 10 July 2011. 
  140. ^ Walitza, Susanne, et al. (June 2007). "Does Methylphenidate Cause a Cytogenetic Effect in Children with Attention Deficit Hyperactivity Disorder?". Environmental Health Perspectives 115 (6): 936–940. doi:10.1289/ehp.9866. PMC 1892117. PMID 17589603. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1892117. 
  141. ^ Schlander (2007). "Long-acting medications for the hyperkinetic disorders: a note on cost-effectiveness". European Child and Adolescent Psychiatry 16 (7): 421–429 (Page:421). doi:10.1007/s00787-007-0615-2. PMID 17401606. [1]
  142. ^ http://www.healthcentral.com/adhd/c/7930/23979/adhds-history-effects
  143. ^ Charles Bradley, M.D., 1902–1979, retrieved September 15, 2008. American Journal of Psychiatry, 155:968
  144. ^ D. Bearman, Cannabis Efficacy in Treating ADD & ADHD. Third National Clinical Conference on Cannabis Therapeutics, May 2004 at Google Videos (Adobe Flash video)
  145. ^ Vlahos, Kelley Beaucar (20 April 2004). "Cannabis 'Scrips to Calm Kids?". Fox News Channel. http://www.foxnews.com/story/0,2933,117541,00.html. Retrieved 26 April 2009. 
  146. ^ Leweke FM, Koethe D (June 2008). "Cannabis and psychiatric disorders: it is not only addiction". Addict Biol 13 (2): 264–75. doi:10.1111/j.1369-1600.2008.00106.x. PMID 18482435. 
  147. ^ Rubino T, Parolaro D (April 2008). "Long lasting consequences of cannabis exposure in adolescence". Mol. Cell. Endocrinol. 286 (1-2 Suppl 1): S108–13. doi:10.1016/j.mce.2008.02.003. PMID 18358595. 
  148. ^ "Cannabis dependence". http://www.wrongdiagnosis.com/c/cannabis_dependence/intro.htm. 
  149. ^ Greydanus DE, Pratt HD, Patel DR (February 2007). "Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult". Disease-a-month 53 (2): 70–131. doi:10.1016/j.disamonth.2007.01.001. PMID 17386306. 
  150. ^ Holtmann M, Stadler C, Leins U, Strehl U, Birbaumer N, Poustka F (July 2004). "[Neurofeedback for the treatment of attention-deficit/hyperactivity disorder (ADHD) in childhood and adolescence]" (in German). Z Kinder Jugendpsychiatr Psychother 32 (3): 187–200. doi:10.1024/1422-4917.32.3.187. PMID 15357015. 
  151. ^ Gevensleben H, Holl B, Albrecht B, Vogel C, Schlamp D, Kratz O, Studer P, Rothenberger A, Moll G H, Heinrich H (July 2009). "[Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial"]. Journal of Child Psychology and Psychiatry 50 (7): 780–789. doi:10.1111/j.1469-7610.2008.02033.x. PMID 19207632. http://www.piero-rossi.ch/download/gevensleben.pdf. 
  152. ^ Loo SK, Barkley RA (2005). "Clinical utility of EEG in attention deficit hyperactivity disorder". Appl Neuropsychol 12 (2): 64–76. doi:10.1207/s15324826an1202_2. PMID 16083395. 
  153. ^ Holtmann M, Stadler C (April 2006). "Electroencephalographic biofeedback for the treatment of attention-deficit hyperactivity disorder in childhood and adolescence". Expert Review of Neurotherapeutics 6 (4): 533–40. doi:10.1586/14737175.6.4.533. PMID 16623652. 
  154. ^ a b Holtmann M, Stadler C, Leins U, Strehl U, Birbaumer N, Poustka F (July 2004). "[Neurofeedback for the treatment of attention-deficit/hyperactivity disorder (ADHD) in childhood and adolescence]" (in German). Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie 32 (3): 187–200. doi:10.1024/1422-4917.32.3.187. PMID 15357015. 
  155. ^ Fox DJ, Tharp DF, Fox LC (December 2005). "Neurofeedback: an alternative and efficacious treatment for Attention Deficit Hyperactivity Disorder". Applied Psychophysiology and Biofeedback 30 (4): 365–73. doi:10.1007/s10484-005-8422-3. PMID 16385424. 
  156. ^ Heinrich H, Gevensleben H, Freisleder FJ, Moll GH, Rothenberger A (April 2004). "Training of slow cortical potentials in attention-deficit/hyperactivity disorder: evidence for positive behavioral and neurophysiological effects". Biological Psychiatry 55 (7): 772–5. doi:10.1016/j.biopsych.2003.11.013. PMID 15039008. 
  157. ^ Hillman, C.; Buck, S.M.; Themanson, J.R.; Pontifex, M.B; Castelli, D.M. (2009). "Aerobic fitness and cognitive development: Event-related brain potential and task performance indices of executive control in preadolescent children". Developmental Psychology 45 (1): 114–125. doi:10.1037/a0014437. PMID 19209995. 
  158. ^ Lopez-Williams Andy, Chacko Anil, Wymbs Brian T, Fabiano Gregory A, Seymour K. E., Gnagy E. M., Chronis A. M., Burrows-Maclean L. et al. (2005). "Athletic Performance and Social Behavior as Predictors of Peer Acceptance in Children Diagnosed With Attention-Deficit/Hyperactivity Disorder". Journal of Emotional and Behavioral Disorders 13 (3): 173–180. doi:10.1177/10634266050130030501. 
  159. ^ Field T., Quintino O., Hernandez-Reif M., Koslovsky G. (1998). "Adolescents with attention deficit hyperactivity disorder benefit from massage therapy". Adolescence 33: 103–108. 
  160. ^ Khilnani S., Field T., Hernandez-Reif M., Schanberg S. (2003). "Massage therapy improves mood and behavior of students with attention-deficit/hyperactivity disorder". Adolescence 38: 623–38. 
  161. ^ Zimmerman FJ, Christakis DA (November 2007). "Associations between content types of early media exposure and subsequent attentional problems". Pediatrics 120 (5): 986–92. doi:10.1542/peds.2006-3322. PMID 17974735. 
  162. ^ Lawson, W. (March 1, 2004). "ADHD's Outdoor Cure". Psychology Today. http://www.psychologytoday.com/articles/200404/adhds-outdoor-cure. Retrieved 2009-11-11. 
  163. ^ a b Johnson M, Ostlund S, Fransson G, Kadesjö B, Gillberg C (March 2009). "Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents". Journal of Attention Disorders 12 (5): 394–401. doi:10.1177/1087054708316261. PMID 18448859. 
  164. ^ "Diet and attention deficit hyperactivity disorder." Harvard Mental Health Letter. June 2009
  165. ^ "FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides". Food and Drug Administration. September 21, 2007. Archived from the original on February 21, 2008. http://web.archive.org/web/20080221173118/http://www.fda.gov/cder/drug/infopage/ADHD/default.htm. Retrieved 2009-04-13. 
  166. ^ S. HIRAYAMA,Y. MASUDA,R. RABELER. "Effect of phosphatidylserine administration on symptoms of Attention-deficit/hyperactivity disorder in children". Agro Food 17 (5): 32–36. http://d.wanfangdata.com.cn/NSTLQK_NSTL_QK13391780.aspx. 
  167. ^ Arnold LE, DiSilvestro RA (2005). "Zinc in attention-deficit/hyperactivity disorder". Journal of child and adolescent psychopharmacology 15 (4): 619–27. doi:10.1089/cap.2005.15.619. PMID 16190793. 
  168. ^ Kadziela-Olech H, Piotrowska-Jastrzebska J. (2005). "The duration of breastfeeding and attention deficit hyperactivity disorder". Rocz Akad Med Bialymst 50: 302–6. PMID 16358988. 
  169. ^ Antalis C, Stevens L, Campbell M, Pazdro R, Ericson K, Burgess J (2006). "Omega-3 fatty acid status in attention-deficit/hyperactivity disorder". Prostaglandins Leukot Essent Fatty Acids 75 (4-5): 299–308. doi:10.1016/j.plefa.2006.07.004. PMID 16962757. 
  170. ^ a b Sinn N, Bryan J (2007). "Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD". Journal of developmental and behavioral pediatrics : JDBP 28 (2): 82–91. doi:10.1097/01.DBP.0000267558.88457.a5. PMID 17435458. 
  171. ^ Ross BM, McKenzie I, Glen I, Bennett CP (2003). "Increased levels of ethane, a non-invasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder". Nutritional neuroscience 6 (5): 277–81. doi:10.1080/10284150310001612203. PMID 14609313. 
  172. ^ Alexandra J. Richardson / Paul Montgomery (2005): The Oxford-Durham Study: A Randomized, Controlled Trial of Dietary Supplementation With Fatty Acids in Children With Developmental Coordination Disorder. In: PEDIATRICS Vol. 115 No. 5 May 2005, pp. 1360-1366 (doi:10.1542/peds.2004-2164)
  173. ^ "Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders." Magnes Res. 2006 Mar;19(1):46-52. PMID 16846100
  174. ^ Konofal E, Cortese S, Lecendreux M, Arnulf I, Mouren MC (2005). "Effectiveness of iron supplementation in a young child with attention-deficit/hyperactivity disorder". Pediatrics 116 (5): e732–4. doi:10.1542/peds.2005-0715. PMID 16263988. 
  175. ^ Haslam, RHA, Dalby, JT, Rademaker, AW. (1984). "Effects of megavitamin therapy on children with attention deficit disorders". Pediatrics 74 (1): 103–111. PMID 6234505. 
  176. ^ Dalby, JT. (1985). "Will population decreases in caffeine consumption unveil attention deficit disorders in adults?". Medical Hypotheses 18 (2): 163–167. doi:10.1016/0306-9877(85)90049-0. PMID 3870823. 
  177. ^ Leon, MR. "Effects of caffeine on cognitive, psychomotor, and affective performance of children with Attention-Deficit/Hyperactivity Disorder".J Atten Disord, April 1, 2000; 4(1): 27 - 47. doi:10.1177/108705470000400103
  178. ^ Eileen O'Connor "A sip into dangerous territory". Monitor on Psychology, Volume 32, No. 5 June 2001. Retrieved on 2007-04-15.
  179. ^ Schnoll R, Burshteyn D, Cea-Aravena J (March 2003). "Nutrition in the treatment of attention-deficit hyperactivity disorder: a neglected but important aspect.". Applied psychophysiology and biofeedback 28 (1): 63–75. doi:10.1023/A:1022321017467. PMID 12737097. 
  180. ^ Krummel DA, Seligson FH, Guthrie HA (1996). "Hyperactivity: is candy causal?". Critical Reviews in Food Science & Nutrition 36 (1-2): 31–47. doi:10.1080/10408399609527717. PMID 8747098. 
  181. ^ Schab DW, Trinh NH (2004). "Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials". Journal of developmental and behavioral pediatrics : JDBP 25 (6): 423–34. doi:10.1097/00004703-200412000-00007. PMID 15613992. 
  182. ^ Bateman B, Warner JO, Hutchinson E, Dean T, Rowlandson P, Gant C, Grundy J, Fitzgerald C, Stevenson J. (2004). "The effects of a double blind, placebo controlled, artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children.". Archives of Disease in Childhood 89 (6): 506–11. doi:10.1136/adc.2003.031435. PMC 1719942. PMID 15155391. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1719942. 
  183. ^ Donna McCann et al. (2007). "Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial". The Lancet in press. 
  184. ^ "Europe-wide call for food colour ban | Manufacturing | ICM Commercial & Business News". http://news.icm.ac.uk/business/retail/europe-wide-call-for-food-colour-ban/419/. 
  185. ^ "Modernising the Rules on Food Additives and Labelling of Azo Dyes - Food Industry News". http://www.flex-news-food.com/console/PageViewer.aspx?page=17642. 
  186. ^ Sukhodolsky DG, Scahill L, Zhang H, et al. Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry. 2003 Jan;42(1) 98-105. PMID 12500082
    * Hoekstra PJ, Steenhuis MP, Troost PW, et al. Relative contribution of attention-deficit hyperactivity disorder, obsessive-compulsive disorder, and tic severity to social and behavioral problems in tic disorders. J Dev Behav Pediatr. 2004 Aug;25(4) 272-9. PMID 15308928
    * Carter AS, O'Donnell DA, Schultz RT, et al. Social and emotional adjustment in children affected with Gilles de la Tourette's syndrome: associations with ADHD and family functioning. Attention Deficit Hyperactivity Disorder. J Child Psychol Psychiatry. 2000 Feb;41(2) 215-23. PMID 10750547
    * Spencer T, Biederman J, Harding M, O'Donnell D, Wilens T, Faraone S, Coffey B, Geller D (Oct 1998). "Disentangling the overlap between Tourette's disorder and ADHD". J Child Psychol Psychiatry 39 (7): 1037–44. doi:10.1111/1469-7610.00406. PMID 9804036. 
  187. ^ a b Freeman, RD. Tourette's Syndrome: minimizing confusion. Retrieved on 8 February 2006. RD Freeman, MD, is Clinic Head of Neuropsychiatry Clinic at British Columbia Children's Hospital, Vancouver, professional advisory board member of Tourette Syndrome Foundation of Canada, and former member of the Tourette Syndrome Association Medical Advisory Board. Dr. Freeman has over 180 journal-published articles on PubMed.
  188. ^ Palumbo D, Spencer T, Lynch J, et al. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol. 2004 Summer;14(2):185-94. PMID 15319016
    * Kurlan R. Tourette's syndrome: are stimulants safe? Curr Neurol Neurosci Rep. 2003 Jul;3(4):285-8. PMID 12930697
    * Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):944-51. PMID 10434485
    * Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics. 1999 Apr;103 (4 Pt 1):730-7. PMID 10103294
  189. ^ Tourette's Syndrome Study Group (February 2002). "Treatment of ADHD in children with tics: a randomized controlled trial.". Neurology 58 (4): 527–36. PMID 11865128. 
  190. ^ Zinner SH (November 2000). "Tourette disorder.". Pediatrics in review / American Academy of Pediatrics 21 (11): 372–83. PMID 11077021. 
  191. ^ a b Scahill L, Erenberg G, Berlin Jr CM, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA et al. (April 2006). "Contemporary assessment and pharmacotherapy of Tourette syndrome.". NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics 3 (2): 192–206. doi:10.1016/j.nurx.2006.01.009. PMID 16554257. 
Main articles
Sub-types
ADHD predominantly inattentive (ADHD-I, formerly ADD) · ADHD predominantly hyperactive (ADHD-H, formerly ADHD) · ADHD combined type (ADHD-C)
Notable publications
Notable experts
Relevant drugs
methylphenidate (Ritalin) · dextroamphetamine (Dexedrine) · mixed amphetamine salts (Adderall) · Non-stimulant: Atomoxetine (Strattera) · More...
Other

M: PSO/PSI

mepr

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc(eval/thrp), drug(N5A/5B/5C/6A/6B/6D)